Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC

被引:15
|
作者
Roncari, B.
Pedroni, M.
Maffei, S.
Di Gregorio, C.
Ponti, G.
Scarselli, A.
Losi, L.
Benatti, P.
Roncucci, L.
De Gaetani, C.
Camellini, L.
Lucci-Cordisco, E.
Tricarico, R.
Genuardi, M.
de Leon, M. Ponz
机构
[1] Univ Modena & Reggio Emilia, Dept Med & Med Specialities, I-41100 Modena, Italy
[2] Civil Hosp Carpi, Pathol Unit, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Pathol, Modena, Italy
[4] Santa Maria Nuova Hosp, Gastrointestinal Endoscopy Unit, Reggio Emilia, Italy
[5] Catholic Univ A Germelli Sch Med, Inst Med Genet, Rome, Italy
[6] Univ Florence, Sch Med, Dept Clin Pathophysiol, Med Genet Sect, Florence, Italy
关键词
colorectal cancer; HNPCC; immunohistochemistry; MSH6; MSI;
D O I
10.1111/j.1399-0004.2007.00856.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
A large majority of constitutional mutations in hereditary non-polyposis colorectal cancer (HNPCC) are because of the MHL1 or MSH2 genes. In a lower fraction of cases, another gene of the mismatch repair (MMR) machinery, MSH6, may be responsible. Families with MSH6 mutations are difficult to recognize, as microsatellite instability (MSI) may not be detectable and immunohistochemistry (IHC) may give ambiguous results. In the present study, we proposed (i) to determine the frequency of MSH6 mutations in a selected population of colorectal cancer patients obtained from a tumor registry, (ii) to assess whether IHC is a suitable tool for selecting and identifying MSH6 mutation carriers. One hundred neoplasms of the large bowel from suspected HNPCC families were analyzed for MSI (BAT25 and BAT26 markers) and immunohistochemical expression of the MSH6 protein. We found on 12 tumors (from different families) showing instability or lack of MSH6 expression. Among these, four potentially pathogenic MSH6 mutations were detected (del A at 2984; del TT at 3119; del AGG cod 385; and del CGT cod 1242) by direct gene sequencing. These represented 12.9% of all families with constitutional mutations of the DNA MMR genes. Thus, some 5% of all HNPCC families are featured by constitutional mutation of the MSH6 gene. This appears, however, as a minimum estimate; routine use of IHC and the study of large numbers of individuals and families with little or no evidence of Lynch syndrome might reveal that mutation of this gene account for a large fraction of HNPCC.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 50 条
  • [31] Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment
    Belvederesi, Laura
    Bianchi, Francesca
    Loretelli, Cristian
    Bracci, Raffaella
    Cascinu, Stefano
    Cellerino, Riccardo
    FAMILIAL CANCER, 2012, 11 (04) : 675 - 680
  • [32] Association of MUTYH and MSH6 germline mutations in colorectal cancer patients
    María Dolores Giráldez
    Francesc Balaguer
    Trinidad Caldés
    Ana Sanchez-de-Abajo
    Nuria Gómez-Fernández
    Clara Ruiz-Ponte
    Jenifer Muñoz
    Pilar Garre
    Victoria Gonzalo
    Leticia Moreira
    Teresa Ocaña
    Joan Clofent
    Angel Carracedo
    Montserrat Andreu
    Rodrigo Jover
    Xavier Llor
    Antoni Castells
    Sergi Castellví-Bel
    Familial Cancer, 2009, 8 : 525 - 531
  • [33] MSH6 somatic mutations in mediating temozolomide resistance in recurrent glioblastomas
    Miao, Jiangyong
    Yip, Stephen
    Cahill, Daniel
    Lafrate, A. John
    Aldape, Ken
    Nutt, Catherine
    Louis, David
    CANCER RESEARCH, 2009, 69
  • [34] MSH6 missense mutations are often associated with no or low cancer susceptibility
    Kariola, R
    Hampel, H
    Frankel, WL
    Raevaara, TE
    de la Chapelle, A
    Nyströ-Lahti, M
    BRITISH JOURNAL OF CANCER, 2004, 91 (07) : 1287 - 1292
  • [35] MSH6 Mutations are Frequent in Hereditary Nonpolyposis Colorectal Cancer Families With Normal pMSH6 Expression as Detected by Immunohistochemistry
    Okkels, Henrik
    Lindorff-Larsen, Karen
    Thorlasius-Ussing, Ole
    Vyberg, Mogens
    Lindebjerg, Jan
    Sunde, Lone
    Bernstein, Inge
    Klarskov, Louise
    Holck, Susanne
    Krarup, Henrik Bygum
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (05) : 470 - 477
  • [36] MSH6 missense mutations are often associated with no or low cancer susceptibility
    R Kariola
    H Hampel
    W L Frankel
    T E Raevaara
    A de la Chapelle
    M Nyström-Lahti
    British Journal of Cancer, 2004, 91 : 1287 - 1292
  • [37] Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor
    Plaschke, J
    Linnebacher, M
    Kloor, M
    Gebert, J
    Cremer, FW
    Tinschert, S
    Aust, DE
    Doeberitz, MVK
    Schackert, HK
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2006, 14 (05) : 561 - 566
  • [38] Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor
    Jens Plaschke
    Michael Linnebacher
    Matthias Kloor
    Johannes Gebert
    Friedrich W Cremer
    Sigrid Tinschert
    Daniela E Aust
    Magnus von Knebel Doeberitz
    Hans K Schackert
    European Journal of Human Genetics, 2006, 14 : 561 - 566
  • [39] Case Report: Malignant Brain Tumors in Siblings With MSH6 Mutations
    Wu, Di
    Chen, Qingshan
    Chen, Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients
    Wiljo JF de Leeuw
    Marjo van Puijenbroek
    Renee Merx
    Juul Th Wijnen
    Annette HJT Bröcker-Vriends
    Carli Tops
    Hans Vasen
    Cees J Cornelisse
    Hans Morreau
    Oncogene, 2001, 20 : 6241 - 6244